Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar

Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR and Boorjian SA: Gender and bladder cancer: A collaborative review of etiology, biology, and outcomes. Eur Urol. 69:300–310. 2016.PubMed/NCBI View Article : Google Scholar

Richters A, Aben KKH and Kiemeney LALM: The global burden of urinary bladder cancer: An update. World J Urol. 38:1895–1904. 2020.PubMed/NCBI View Article : Google Scholar

Xia Y, Chen R, Lu G, Li C, Lian S, Kang TW and Jung YD: Natural phytochemicals in bladder cancer prevention and therapy. Front Oncol. 11(652033)2021.PubMed/NCBI View Article : Google Scholar

Han J, Gu X, Li Y and Wu Q: Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 129(110393)2020.PubMed/NCBI View Article : Google Scholar

Kimura T, Ishikawa H, Kojima T, Kandori S, Kawahara T, Sekino Y, Sakurai H and Nishiyama H: Bladder preservation therapy for muscle invasive bladder cancer: The past, present and future. Jpn J Clin Oncol. 50:1097–1107. 2020.PubMed/NCBI View Article : Google Scholar

Tran L, Xiao JF, Agarwal N, Duex JE and Theodorescu D: Advances in bladder cancer biology and therapy. Nat Rev Cancer. 21:104–121. 2021.PubMed/NCBI View Article : Google Scholar

Bednova O and Leyton JV: Targeted molecular therapeutics for bladder cancer-A new option beyond the mixed fortunes of immune checkpoint inhibitors? Int J Mol Sci. 21(7268)2020.PubMed/NCBI View Article : Google Scholar

Rutz J, Janicova A, Woidacki K, Chun FK, Blaheta RA and Relja B: Curcumin-A viable agent for better bladder cancer treatment. Int J Mol Sci. 21(3761)2020.PubMed/NCBI View Article : Google Scholar

Zanoaga O, Braicu C, Jurj A, Rusu A, Buiga R and Berindan-Neagoe I: Progress in research on the role of flavonoids in lung cancer. Int J Mol Sci. 20(4291)2019.PubMed/NCBI View Article : Google Scholar

Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Anticancer efficacy of polyphenols and their combinations. Nutrients. 8(552)2016.PubMed/NCBI View Article : Google Scholar

Kumar S and Pandey AK: Chemistry and biological activities of flavonoids: An overview. ScientificWorldJournal. 2013(162750)2013.PubMed/NCBI View Article : Google Scholar

Amawi H, Ashby CR Jr and Tiwari AK: Cancer chemoprevention through dietary flavonoids: What's limiting? Chin J Cancer. 36(50)2017.PubMed/NCBI View Article : Google Scholar

Lama-Sherpa TD and Shevde LA: An emerging regulatory role for the tumor microenvironment in the DNA damage response to double-strand breaks. Mol Cancer Res. 18:185–193. 2020.PubMed/NCBI View Article : Google Scholar

Srinivas US, Tan BWQ, Vellayappan BA and Jeyasekharan AD: ROS and the DNA damage response in cancer. Redox Biol. 25(101084)2019.PubMed/NCBI View Article : Google Scholar

Harashima H, Dissmeyer N and Schnittger A: Cell cycle control across the eukaryotic kingdom. Trends Cell Biol. 23:345–356. 2013.PubMed/NCBI View Article : Google Scholar

Lim S and Kaldis P: Cdks, cyclins and CKIs: Roles beyond cell cycle regulation. Development. 140:3079–3093. 2013.PubMed/NCBI View Article : Google Scholar

Carusillo A and Mussolino C: DNA Damage: From threat to treatment. Cells. 9(1665)2020.PubMed/NCBI View Article : Google Scholar

Solier S, Zhang YW, Ballestrero A, Pommier Y and Zoppoli G: DNA damage response pathways and cell cycle checkpoints in colorectal cancer: Current concepts and future perspectives for targeted treatment. Curr Cancer Drug Targets. 12:356–371. 2012.PubMed/NCBI View Article : Google Scholar

Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature. 432:316–323. 2004.PubMed/NCBI View Article : Google Scholar

de Sá Junior PL, Câmara DAD, Porcacchia AS, Fonseca PMM, Jorge SD, Araldi RP and Ferreira AK: The roles of ROS in cancer heterogeneity and therapy. Oxid Med Cell Longev. 2017(2467940)2017.PubMed/NCBI View Article : Google Scholar

Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, Varol M, Jain A, Khan MA and Sethi G: Role of reactive oxygen species in cancer progression: Molecular mechanisms and recent advancements. Biomolecules. 9(735)2019.PubMed/NCBI View Article : Google Scholar

Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, Castoria G and Migliaccio A: ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 52:192–203. 2020.PubMed/NCBI View Article : Google Scholar

Xu X, Lai Y and Hua ZC: Apoptosis and apoptotic body: Disease message and therapeutic target potentials. Biosci Rep. 39(BSR20180992)2019.PubMed/NCBI View Article : Google Scholar

Hengartner MO: Apoptosis: Corralling the corpses. Cell. 104:325–328. 2001.PubMed/NCBI View Article : Google Scholar

Schneider P and Tschopp J: Apoptosis induced by death receptors. Pharm Acta Helv. 74:281–286. 2000.PubMed/NCBI View Article : Google Scholar

Indran IR, Tufo G, Pervaiz S and Brenner C: Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011.PubMed/NCBI View Article : Google Scholar

Bertheloot D, Latz E and Franklin BS: Necroptosis, pyroptosis and apoptosis: An intricate game of cell death. Cell Mol Immunol. 18:1106–1121. 2021.PubMed/NCBI View Article : Google Scholar

Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30(87)2011.PubMed/NCBI View Article : Google Scholar

Szegezdi E, Fitzgerald U and Samali A: Caspase-12 and ER-stress-mediated apoptosis: The story so far. Ann N Y Acad Sci. 1010:186–194. 2003.PubMed/NCBI View Article : Google Scholar

Levy JMM, Towers CG and Thorburn A: Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.PubMed/NCBI View Article : Google Scholar

Amaravadi RK, Kimmelman AC and Debnath J: Targeting autophagy in cancer: Recent advances and future directions. Cancer Discov. 9:1167–1181. 2019.PubMed/NCBI View Article : Google Scholar

White E, Mehnert JM and Chan CS: Autophagy, metabolism, and cancer. Clin Cancer Res. 21:5037–5046. 2015.PubMed/NCBI View Article : Google Scholar

Amaravadi R, Kimmelman AC and White E: Recent insights into the function of autophagy in cancer. Genes Dev. 30:1913–1930. 2016.PubMed/NCBI View Article : Google Scholar

Mou Y, Wang J, Wu J, He D, Zhang C, Duan C and Li B: Ferroptosis, a new form of cell death: Opportunities and challenges in cancer. J Hematol Oncol. 12(34)2019.PubMed/NCBI View Article : Google Scholar

Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W and Wang J: Molecular mechanisms of ferroptosis and its role in cancer therapy. J Cell Mol Med. 23:4900–4912. 2019.PubMed/NCBI View Article : Google Scholar

Bebber CM, Müller F, Prieto Clemente L, Weber J and von Karstedt S: Ferroptosis in cancer cell biology. Cancers (Basel). 12(164)2020.PubMed/NCBI View Article : Google Scholar

Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, Sun B and Wang G: Ferroptosis: past, present and future. Cell Death Dis. 11(88)2020.PubMed/NCBI View Article : Google Scholar

Tiffon C: The impact of nutrition and environmental epigenetics on human health and disease. Int J Mol Sci. 19(3425)2018.PubMed/NCBI View Article : Google Scholar

Margueron R and Reinberg D: Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet. 11:285–296. 2010.PubMed/NCBI View Article : Google Scholar

Mahmoud AM and Ali MM: Methyl donor micronutrients that modify DNA methylation and cancer outcome. Nutrients. 11(608)2019.PubMed/NCBI View Article : Google Scholar

Jasek K, Kubatka P, Samec M, Liskova A, Smejkal K, Vybohova D, Bugos O, Biskupska-Bodova K, Bielik T, Zubor P, et al: DNA methylation status in cancer disease: Modulations by plant-derived natural compounds and dietary interventions. Biomolecules. 9(289)2019.PubMed/NCBI View Article : Google Scholar

Huang Z, Huang Q, Ji L, Wang Y, Qi X, Liu L, Liu Z and Lu L: Epigenetic regulation of active Chinese herbal components for cancer prevention and treatment: A follow-up review. Pharmacol Res. 114:1–12. 2016.PubMed/NCBI View Article : Google Scholar

Qin J, Wen B, Liang Y, Yu W and Li H: Histone modifications and their role in colorectal cancer (Review). Pathol Oncol Res. 26:2023–2033. 2020.PubMed/NCBI View Article : Google Scholar

Audia JE and Campbell RM: Histone modifications and cancer. Cold Spring Harb Perspect Biol. 8(a019521)2016.PubMed/NCBI View Article : Google Scholar

Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009.PubMed/NCBI View Article : Google Scholar

Ali Syeda Z, Langden SSS, Munkhzul C, Lee M and Song SJ: Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci. 21(1723)2020.PubMed/NCBI View Article : Google Scholar

Tay Y, Rinn J and Pandolfi PP: The multilayered complexity of ceRNA crosstalk and competition. Nature. 505:344–352. 2014.PubMed/NCBI View Article : Google Scholar

Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996.PubMed/NCBI View Article : Google Scholar

Koch AE and Distler O: Vasculopathy and disordered angiogenesis in selected rheumatic diseases: Rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther. 9 (Suppl 2)(S3)2007.PubMed/NCBI View Article : Google Scholar

Ramjiawan RR, Griffioen AW and Duda DG: Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 20:185–204. 2017.PubMed/NCBI View Article : Google Scholar

Rajabi M and Mousa SA: The role of angiogenesis in cancer treatment. Biomedicines. 5(34)2017.PubMed/NCBI View Article : Google Scholar

Pan G, Liu Y, Shang L, Zhou F and Yang S: EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun (Lond). 41:199–217. 2021.PubMed/NCBI View Article : Google Scholar

Eun K, Ham SW and Kim H: Cancer stem cell heterogeneity: Origin and new perspectives on CSC targeting. BMB Rep. 50:117–125. 2017.PubMed/NCBI View Article : Google Scholar

Barzegar Behrooz A, Syahir A and Ahmad S: CD133: Beyond a cancer stem cell biomarker. J Drug Target. 27:257–269. 2019.PubMed/NCBI View Article : Google Scholar

Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B and Cheng SY: Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 10:8721–8743. 2020.PubMed/NCBI View Article : Google Scholar

Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014.PubMed/NCBI View Article : Google Scholar

Du B and Shim JS: Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 21(965)2016.PubMed/NCBI View Article : Google Scholar

Lehman HL, Kidacki M and Stairs DB: Twist2 is NFkB-responsive when p120-catenin is inactivated and EGFR is overexpressed in esophageal keratinocytes. Sci Rep. 10(18829)2020.PubMed/NCBI View Article : Google Scholar

Luongo F, Colonna F, Calapà F, Vitale S, Fiori ME and De Maria R: PTEN tumor-suppressor: The dam of stemness in cancer. Cancers (Basel). 11(1076)2019.PubMed/NCBI View Article : Google Scholar

Kopustinskiene DM, Jakstas V, Savickas A and Bernatoniene J: Flavonoids as anticancer agents. Nutrients. 12(457)2020.PubMed/NCBI View Article : Google Scholar

Abotaleb M, Samuel SM, Varghese E, Varghese S, Kubatka P, Liskova A and Büsselberg D: Flavonoids in cancer and apoptosis. Cancers (Basel). 11(28)2018.PubMed/NCBI View Article : Google Scholar

Panche AN, Diwan AD and Chandra SR: Flavonoids: An overview. J Nutr Sci. 5(e47)2016.PubMed/NCBI View Article : Google Scholar

Hostetler GL, Ralston RA and Schwartz SJ: Flavones: Food sources, bioavailability, metabolism, and bioactivity. Adv Nutr. 8:423–435. 2017.PubMed/NCBI View Article : Google Scholar

Shi MD, Shiao CK, Lee YC and Shih YW: Apigenin, a dietary flavonoid, inhibits proliferation of human bladder cancer T-24 cells via blocking cell cycle progression and inducing apoptosis. Cancer Cell Int. 15(33)2015.PubMed/NCBI View Article : Google Scholar

Zhu Y, Mao Y, Chen H, Lin Y, Hu Z, Wu J, Xu X, Xu X, Qin J and Xie L: Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell Int. 13(54)2013.PubMed/NCBI View Article : Google Scholar

Xia Y, Yuan M, Li S, Thuan UT, Nguyen TT, Kang TW, Liao W, Lian S and Jung YD: Apigenin Suppresses the IL-1β-induced expression of the urokinase-type plasminogen activator receptor by inhibiting MAPK-Mediated AP-1 and NF-κB signaling in human bladder cancer T24 cells. J Agric Food Chem. 66:7663–7673. 2018.PubMed/NCBI View Article : Google Scholar

Lin Y, Shi R, Wang X and Shen HM: Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 8:634–646. 2008.PubMed/NCBI View Article : Google Scholar

Kilani-Jaziri S, Frachet V, Bhouri W, Ghedira K, Chekir-Ghedira L and Ronot X: Flavones inhibit the proliferation of human tumor cancer cell lines by inducing apoptosis. Drug Chem Toxicol. 35:1–10. 2012.PubMed/NCBI View Article : Google Scholar

Iida K, Naiki T, Naiki-Ito A, Suzuki S, Kato H, Nozaki S, Nagai T, Etani T, Nagayasu Y, Ando R, et al: Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway. Cancer Sci. 111:1165–1179. 2020.PubMed/NCBI View Article : Google Scholar

Yang G, Wang Z, Wang W, Zhou X, Hu X and Yang J: Anticancer activity of Luteolin and its synergism effect with BCG on human bladder cancer cell line BIU-87. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 39:371–378. 2014.PubMed/NCBI View Article : Google Scholar : (In Chinese).

Lin JJ, Huang CC, Su YL, Luo HL, Lee NL, Sung MT and Wu YJ: Proteomics analysis of tangeretin-induced apoptosis through mitochondrial dysfunction in bladder cancer cells. Int J Mol Sci. 20(1017)2019.PubMed/NCBI View Article : Google Scholar

Mani R and Natesan V: Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. Phytochemistry. 145:187–196. 2018.PubMed/NCBI View Article : Google Scholar

Xu Y, Tong Y, Ying J, Lei Z, Wan L, Zhu X, Ye F, Mao P, Wu X, Pan R, et al: Chrysin induces cell growth arrest, apoptosis, and ER stress and inhibits the activation of STAT3 through the generation of ROS in bladder cancer cells. Oncol Lett. 15:9117–9125. 2018.PubMed/NCBI View Article : Google Scholar

Lima APB, Almeida TC, Barros TMB, Rocha LCM, Garcia CCM and da Silva GN: Toxicogenetic and antiproliferative effects of chrysin in urinary bladder cancer cells. Mutagenesis: Aug 13, 2020 (Epub ahead of print).

Yang Y, Liu K, Yang L and Zhang G: Bladder cancer cell viability inhibition and apoptosis induction by baicalein through targeting the expression of anti-apoptotic genes. Saudi J Biol Sci. 25:1478–1482. 2018.PubMed/NCBI View Article : Google Scholar

Choi EO, Park C, Hwang HJ, Hong SH, Kim GY, Cho EJ, Kim WJ and Choi YH: Baicalein induces apoptosis via ROS-dependent activation of caspases in human bladder cancer 5637 cells. Int J Oncol. 49:1009–1018. 2016.PubMed/NCBI View Article : Google Scholar

Li HL, Zhang S, Wang Y, Liang RR, Li J, An P, Wang ZM, Yang J and Li ZF: Baicalein induces apoptosis via a mitochondrial-dependent caspase activation pathway in T24 bladder cancer cells. Mol Med Rep. 7:266–270. 2013.PubMed/NCBI View Article : Google Scholar

Kong N, Chen X, Feng J, Duan T, Liu S, Sun X, Chen P, Pan T, Yan L, Jin T, et al: Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1. Acta Pharm Sin B. 11:4045–4054. 2021.PubMed/NCBI View Article : Google Scholar

Wu JY, Tsai KW, Li YZ, Chang YS, Lai YC, Laio YH, Wu JD and Liu YW: Anti-bladder-tumor effect of baicalein from scutellaria baicalensis georgi and its application in vivo. Evid Based Complement Alternat Med. 2013(579751)2013.PubMed/NCBI View Article : Google Scholar

Peng L, Wen L, Shi QF, Gao F, Huang B, Meng J, Hu CP and Wang CM: Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis. 11(978)2020.PubMed/NCBI View Article : Google Scholar

Lv WL, Liu Q, An JH and Song XY: Scutellarin inhibits hypoxia-induced epithelial-mesenchymal transition in bladder cancer cells. J Cell Physiol. 234:23169–23175. 2019.PubMed/NCBI View Article : Google Scholar

Ashrafizadeh M, Zarrabi A, Saberifar S, Hashemi F, Hushmandi K, Hashemi F, Moghadam ER, Mohammadinejad R, Najafi M and Garg M: Nobiletin in cancer therapy: How this plant derived-natural compound targets various oncogene and onco-suppressor pathways. Biomedicines. 8(110)2020.PubMed/NCBI View Article : Google Scholar

Goan YG, Wu WT, Liu CI, Neoh CA and Wu YJ: Involvement of mitochondrial dysfunction, endoplasmic reticulum stress, and the PI3K/AKT/mTOR pathway in nobiletin-induced apoptosis of human bladder cancer cells. Molecules. 24(2881)2019.PubMed/NCBI View Article : Google Scholar

Tian F, Tong M, Li Z, Huang W, Jin Y, Cao Q, Zhou X and Tong G: The effects of orientin on proliferation and apoptosis of T24 human bladder carcinoma cells occurs through the inhibition of nuclear factor-kappaB and the hedgehog signaling pathway. Med Sci Monit. 25:9547–9554. 2019.PubMed/NCBI View Article : Google Scholar

Stavric B: Quercetin in our diet: From potent mutagen to probable anticarcinogen. Clin Biochem. 27:245–248. 1994.PubMed/NCBI View Article : Google Scholar

Rauf A, Imran M, Khan IA, Ur-Rehman M, Gilani SA, Mehmood Z and Mubarak MS: Anticancer potential of quercetin: A comprehensive review. Phytother Res. 32:2109–2130. 2018.PubMed/NCBI View Article : Google Scholar

Adami BS, Diz FM, Oliveira Gonçalves GP, Reghelin CK, Scherer M, Dutra AP, Papaléo RM, de Oliveira JR, Morrone FB, Wieck A and Xavier LL: Morphological and mechanical changes induced by quercetin in human T24 bladder cancer cells. Micron. 151(103152)2021.PubMed/NCBI View Article : Google Scholar

Oršolić N, Karač I, Sirovina D, Kukolj M, Kunštić M, Gajski G, Garaj-Vrhovac V and Štajcar D: Chemotherapeutic potential of quercetin on human bladder cancer cells. J Environ Sci Health A Tox Hazard Subst Environ Eng. 51:776–781. 2016.PubMed/NCBI View Article : Google Scholar

Su Q, Peng M, Zhang Y, Xu W, Darko KO, Tao T, Huang Y, Tao X and Yang X: Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. Am J Cancer Res. 6:498–508. 2016.PubMed/NCBI

Wei L, Liu JJ, Cao J, Du NC, Ji LN and Yang XL: Role of autophagy in quercetin-induced apoptosis in human bladder carcinoma BIU-87 cells. Zhonghua Zhong Liu Za Zhi. 34:414–418. 2012.PubMed/NCBI(In Chinese).

Tan DQ and Liu XH: Mechanism in growth inhibition of quercetin on human bladder cancer cell line. Zhongguo Zhong Yao Za Zhi. 42:1742–1746. 2017.PubMed/NCBI View Article : Google Scholar : (In Chinese).

Rockenbach L, Bavaresco L, Fernandes Farias P, Cappellari AR, Barrios CH, Bueno Morrone F and Oliveira Battastini AM: Alterations in the extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells. Urol Oncol. 31:1204–1211. 2013.PubMed/NCBI View Article : Google Scholar

Berger SI and Iyengar R: Network analyses in systems pharmacology. Bioinformatics. 25:2466–2472. 2009.PubMed/NCBI View Article : Google Scholar

Dong Y, Hao L, Fang K, Han XX, Yu H, Zhang JJ, Cai LJ, Fan T, Zhang WD, Pang K, et al: A network pharmacology perspective for deciphering potential mechanisms of action of Solanum nigrum L. in bladder cancer. BMC Complement Med Ther. 21(45)2021.PubMed/NCBI View Article : Google Scholar

Cho CJ, Yu CP, Wu CL, Ho JY, Yang CW and Yu DS: Decreased drug resistance of bladder cancer using phytochemicals treatment. Kaohsiung J Med Sci. 37:128–135. 2021.PubMed/NCBI View Article : Google Scholar

Oršolić N, Odeh D, Jembrek MJ, Knežević J and Kučan D: Interactions between cisplatin and quercetin at physiological and hyperthermic conditions on cancer cells in vitro and in vivo. Molecules. 25(3271)2020.PubMed/NCBI View Article : Google Scholar

Lee YH and Tuyet PT: Synthesis and biological evaluation of quercetin-zinc (II) complex for anti-cancer and anti-metastasis of human bladder cancer cells. In Vitro Cell Dev Biol Anim. 55:395–404. 2019.PubMed/NCBI View Article : Google Scholar

Tao T, He C, Deng J, Huang Y, Su Q, Peng M, Yi M, Darko KO, Zou H and Yang X: A novel synthetic derivative of quercetin, 8-trifluoromethyl-3,5,7,3',4'-O-pentamethyl-quercetin, inhibits bladder cancer growth by targeting the AMPK/mTOR signaling pathway. Oncotarget. 8:71657–71671. 2017.PubMed/NCBI View Article : Google Scholar

Alban L, Monteiro WF, Diz FM, Miranda GM, Scheid CM, Zotti ER, Morrone FB and Ligabue R: New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer. Mater Sci Eng C Mater Biol Appl. 110(110662)2020.PubMed/NCBI View Article : Google Scholar

Shui L, Wang W, Xie M, Ye B, Li X, Liu Y and Zheng M: Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway. Aging (Albany NY). 12:24318–24332. 2020.PubMed/NCBI View Article : Google Scholar

Chen F, Chen X, Yang D, Che X, Wang J, Li X, Zhang Z, Wang Q, Zheng W, Wang L, et al: Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways. Oncol Rep. 36:165–172. 2016.PubMed/NCBI View Article : Google Scholar

Wu P, Liu S, Su J, Chen J, Li L, Zhang R and Chen T: Apoptosis triggered by isoquercitrin in bladder cancer cells by activating the AMPK-activated protein kinase pathway. Food Funct. 8:3707–3722. 2017.PubMed/NCBI View Article : Google Scholar

Ran J, Wang Y, Zhang W, Ma M and Zhang H: Research on the bioactivity of isoquercetin extracted from marestail on bladder cancer EJ cell and the mechanism of its occurrence. Artif Cells Nanomed Biotechnol. 44:859–864. 2016.PubMed/NCBI View Article : Google Scholar

Imran M, Salehi B, Sharifi-Rad J, Aslam Gondal T, Saeed F, Imran A, Shahbaz M, Tsouh Fokou PV, Umair Arshad M, Khan H, et al: Kaempferol: A key emphasis to its anticancer potential. Molecules. 24(2277)2019.PubMed/NCBI View Article : Google Scholar

Qiu W, Lin J, Zhu Y, Zhang J, Zeng L, Su M and Tian Y: Kaempferol modulates DNA methylation and downregulates DNMT3B in bladder cancer. Cell Physiol Biochem. 41:1325–1335. 2017.PubMed/NCBI View Article : Google Scholar

Wu P, Meng X, Zheng H, Zeng Q, Chen T, Wang W, Zhang X and Su J: Kaempferol attenuates ROS-Induced hemolysis and the molecular mechanism of its induction of apoptosis on bladder cancer. Molecules. 23(2592)2018.PubMed/NCBI View Article : Google Scholar

Dang Q, Song W, Xu D, Ma Y, Li F, Zeng J, Zhu G, Wang X, Chang LS, He D and Li L: Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog. 54:831–840. 2015.PubMed/NCBI View Article : Google Scholar

Xie F, Su M, Qiu W, Zhang M, Guo Z, Su B, Liu J, Li X and Zhou L: Kaempferol promotes apoptosis in human bladder cancer cells by inducing the tumor suppressor, PTEN. Int J Mol Sci. 14:21215–21226. 2013.PubMed/NCBI View Article : Google Scholar

DE Oliveira DT, Savio AL, Marcondes JP, Barros TM, Barbosa LC, Salvadori DM and DA Silva GN: Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status. J Biosci. 42:91–101. 2017.PubMed/NCBI View Article : Google Scholar

Barros TMB, Lima APB, Almeida TC and da Silva GN: Inhibition of urinary bladder cancer cell proliferation by silibinin. Environ Mol Mutagen. 61:445–455. 2020.PubMed/NCBI View Article : Google Scholar

Li F, Sun Y, Jia J, Yang C, Tang X, Jin B, Wang K, Guo P, Ma Z, Chen Y, et al: Silibinin attenuates TGF-β1-induced migration and invasion via EMT suppression and is associated with COX-2 downregulation in bladder transitional cell carcinoma. Oncol Rep. 40:3543–3550. 2018.PubMed/NCBI View Article : Google Scholar

Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, Zhang L, Chen Y, Gao Y, Wang B, et al: Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal. 25:2625–2633. 2013.PubMed/NCBI View Article : Google Scholar

Imai-Sumida M, Chiyomaru T, Majid S, Saini S, Nip H, Dahiya R, Tanaka Y and Yamamura S: Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget. 8:92032–92042. 2017.PubMed/NCBI View Article : Google Scholar

Sun Y, Guan Z, Zhao W, Jiang Y, Li Q, Cheng Y and Xu Y: Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-κB signal-dependent and signal-independent manner. Int J Oncol. 51:1219–1226. 2017.PubMed/NCBI View Article : Google Scholar

Prack Mc Cormick B, Langle Y, Belgorosky D, Vanzulli S, Balarino N, Sandes E and Eiján AM: Flavonoid silybin improves the response to radiotherapy in invasive bladder cancer. J Cell Biochem. 119:5402–5412. 2018.PubMed/NCBI View Article : Google Scholar

Gándara L, Sandes E, Di Venosa G, Prack Mc Cormick B, Rodriguez L, Mamone L, Batlle A, Eiján AM and Casas A: The natural flavonoid silybin improves the response to Photodynamic Therapy of bladder cancer cells. J Photochem Photobiol B. 133:55–64. 2014.PubMed/NCBI View Article : Google Scholar

Ramchandani S, Naz I, Lee JH, Khan MR and Ahn KS: An Overview of the potential antineoplastic effects of casticin. Molecules. 25(1287)2020.PubMed/NCBI View Article : Google Scholar

Xu H, Shi HL, Hao JW, Shu KP, Zhang YT and Hou TQ: Casticin inhibits the proliferation, migration and invasion of bladder cancer cells by inhibition of TM7SF4 expression. Zhonghua Zhong Liu Za Zhi. 44:334–340. 2022.PubMed/NCBI View Article : Google Scholar : (In Chinese).

Huang AC, Cheng YD, Huang LH, Hsiao YT, Peng SF, Lu KW, Lien JC, Yang JL, Lin TS and Chung JG: Casticin induces DNA damage and impairs DNA repair in human bladder cancer TSGH-8301 cells. Anticancer Res. 39:1839–1847. 2019.PubMed/NCBI View Article : Google Scholar

Chung YH and Kim D: RIP kinase-mediated ROS production triggers XAF1 expression through activation of TAp73 in casticin-treated bladder cancer cells. Oncol Rep. 36:1135–1142. 2016.PubMed/NCBI View Article : Google Scholar

Gao X, Xu J, Jiang L, Liu W, Hong H, Qian Y, Li S, Huang W, Zhao H, Yang Z, et al: Morin alleviates aflatoxin B1-induced liver and kidney injury by inhibiting heterophil extracellular traps release, oxidative stress and inflammatory responses in chicks. Poult Sci. 100(101513)2021.PubMed/NCBI View Article : Google Scholar

Shin SS, Won SY, Noh DH, Hwang B, Kim WJ and Moon SK: Morin inhibits proliferation, migration, and invasion of bladder cancer EJ cells via modulation of signaling pathways, cell cycle regulators, and transcription factor-mediated MMP-9 expression. Drug Dev Res. 78:81–90. 2017.PubMed/NCBI View Article : Google Scholar

Pan XW, Li L, Huang Y, Huang H, Xu DF, Gao Y, Chen L, Ren JZ, Cao JW, Hong Y and Cui XG: Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy. Oncol Rep. 35:334–342. 2016.PubMed/NCBI View Article : Google Scholar

Stevens Y, Rymenant EV, Grootaert C, Camp JV, Possemiers S, Masclee A and Jonkers D: The intestinal fate of citrus flavanones and their effects on gastrointestinal health. Nutrients. 11(1464)2019.PubMed/NCBI View Article : Google Scholar

Kim DI, Lee SJ, Lee SB, Park K, Kim WJ and Moon SK: Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. Carcinogenesis. 29:1701–1709. 2008.PubMed/NCBI View Article : Google Scholar

Liao AC, Kuo CC, Huang YC, Yeh CW, Hseu YC, Liu JY and Hsu LS: Naringenin inhibits migration of bladder cancer cells through downregulation of AKT and MMP-2. Mol Med Rep. 10:1531–1536. 2014.PubMed/NCBI View Article : Google Scholar

Juhem A, Boumendjel A, Touquet B, Guillot A, Popov A, Ronot X and Martel-Frachet V: AG11, a novel dichloroflavanone derivative with anti-mitotic activity towards human bladder cancer cells. Anticancer Res. 33:4445–4452. 2013.PubMed/NCBI

Khan N, Afaq F and Mukhtar H: Cancer chemoprevention through dietary antioxidants: Progress and promise. Antioxid Redox Signal. 10:475–510. 2008.PubMed/NCBI View Article : Google Scholar

Khan N and Mukhtar H: Tea polyphenols in promotion of human health. Nutrients. 11(39)2018.PubMed/NCBI View Article : Google Scholar

Bernatoniene J and Kopustinskiene DM: The role of catechins in cellular responses to oxidative stress. Molecules. 23(965)2018.PubMed/NCBI View Article : Google Scholar

Khan N, Afaq F, Saleem M, Ahmad N and Mukhtar H: Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 66:2500–2505. 2006.PubMed/NCBI View Article : Google Scholar

Yasuda T, Miyata Y, Nakamura Y, Sagara Y, Matsuo T, Ohba K and Sakai H: High Consumption of Green tea suppresses urinary tract recurrence of urothelial cancer via down-regulation of human antigen-R expression in never smokers. In Vivo. 32:721–729. 2018.PubMed/NCBI View Article : Google Scholar

Matsuo T, Miyata Y, Asai A, Sagara Y, Furusato B, Fukuoka J and Sakai H: Green tea polyphenol induces changes in cancer-related factors in an animal model of bladder cancer. PLoS One. 12(e0171091)2017.PubMed/NCBI View Article : Google Scholar

Chen Z, Yu T, Zhou B, Wei J, Fang Y, Lu J, Guo L, Chen W, Liu ZP and Luo J: Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo. Biomaterials. 81:125–134. 2016.PubMed/NCBI View Article : Google Scholar

Jankun J, Keck RW and Selman SH: Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model. Int J Oncol. 44:147–152. 2014.PubMed/NCBI View Article : Google Scholar

Lee HY, Chen YJ, Chang WA, Li WM, Ke HL, Wu WJ and Kuo PL: Effects of epigallocatechin gallate (EGCG) on urinary bladder urothelial carcinoma-next-generation sequencing and bioinformatics approaches. Medicina (Kaunas). 55(768)2019.PubMed/NCBI View Article : Google Scholar

Luo KW, Wei Chen, Lung WY, Wei XY, Cheng BH, Cai ZM and Huang WR: EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-κB and MMP-9. J Nutr Biochem. 41:56–64. 2017.PubMed/NCBI View Article : Google Scholar

Luo KW, Lung WY, Chun-Xie Luo XL and Huang WR: EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway. Oncotarget. 9:12261–12272. 2018.PubMed/NCBI View Article : Google Scholar

Qin J, Wang Y, Bai Y, Yang K, Mao Q, Lin Y, Kong D, Zheng X and Xie L: Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Mol Med Rep. 6:1040–1044. 2012.PubMed/NCBI View Article : Google Scholar

Feng C, Ho Y, Sun C, Xia G, Ding Q and Gu B: Epigallocatechin gallate inhibits the growth and promotes the apoptosis of bladder cancer cells. Exp Ther Med. 14:3513–3518. 2017.PubMed/NCBI View Article : Google Scholar

Yin Z, Li J, Kang L, Liu X, Luo J, Zhang L, Li Y and Cai J: Epigallocatechin-3-gallate induces autophagy-related apoptosis associated with LC3B II and Beclin expression of bladder cancer cells. J Food Biochem. 45(e13758)2021.PubMed/NCBI View Article : Google Scholar

Sun X, Song J, Li E, Geng H, Li Y, Yu D and Zhong C: (-)-Epigallocatechin-3-gallate inhibits bladder cancer stem cells via suppression of sonic hedgehog pathway. Oncol Rep. 42:425–435. 2019.PubMed/NCBI View Article : Google Scholar

Luo KW, Zhu XH, Zhao T, Zhong J, Gao HC, Luo XL and Huang WR: EGCG enhanced the anti-tumor effect of doxorubicine in bladder cancer via NF-κB/MDM2/p53 pathway. Front Cell Dev Biol. 8(606123)2020.PubMed/NCBI View Article : Google Scholar

Mottaghipisheh J, Doustimotlagh AH, Irajie C, Tanideh N, Barzegar A and Iraji A: The promising therapeutic and preventive properties of anthocyanidins/anthocyanins on prostate cancer. Cells. 11(1070)2022.PubMed/NCBI View Article : Google Scholar

Alappat B and Alappat J: Anthocyanin pigments: Beyond aesthetics. Molecules. 25(5500)2020.PubMed/NCBI View Article : Google Scholar

Higgins JA, Zainol M, Brown K and Jones GD: Anthocyans as tertiary chemopreventive agents in bladder cancer: Anti-oxidant mechanisms and interaction with mitomycin C. Mutagenesis. 29:227–235. 2014.PubMed/NCBI View Article : Google Scholar

Li WL, Ji GH, Zhang XZ and Yu HY: The influence and mechanisms of purple sweet potato anthocyanins on the growth of bladder cancer BIU87 cell. Zhonghua Yi Xue Za Zhi. 98:457–459. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).

Li WL, Yu HY, Zhang XJ, Ke M and Hong T: Purple sweet potato anthocyanin exerts antitumor effect in bladder cancer. Oncol Rep. 40:73–82. 2018.PubMed/NCBI View Article : Google Scholar

Yang N, Gao J, Hou R, Xu X, Yang N and Huang S: Grape seed proanthocyanidins inhibit migration and invasion of bladder cancer cells by reversing EMT through suppression of TGF-β signaling pathway. Oxid Med Cell Longev. 2021(5564312)2021.PubMed/NCBI View Article : Google Scholar

Fishman AI, Johnson B, Alexander B, Won J, Choudhury M and Konno S: Additively enhanced antiproliferative effect of interferon combined with proanthocyanidin on bladder cancer cells. J Cancer. 3:107–112. 2012.PubMed/NCBI View Article : Google Scholar

Liu J, Zhang WY, Kong ZH and Ding DG: Induction of cell cycle arrest and apoptosis by grape seed procyanidin extract in human bladder cancer BIU87 cells. Eur Rev Med Pharmacol Sci. 20:3282–3291. 2016.PubMed/NCBI

Křížová L, Dadáková K, Kašparovská J and Kašparovský T: Isoflavones. Molecules. 24(1076)2019.PubMed/NCBI View Article : Google Scholar

He Y, Wu X, Cao Y, Hou Y, Chen H, Wu L, Lu L, Zhu W and Gu Y: Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway. Neoplasma. 63:523–531. 2016.PubMed/NCBI View Article : Google Scholar

Russo M, Russo GL, Daglia M, Kasi PD, Ravi S, Nabavi SF and Nabavi SM: Understanding genistein in cancer: The ‘good’ and the ‘bad’ effects: A review. Food Chem. 196:589–600. 2016.PubMed/NCBI View Article : Google Scholar

Park C, Cha HJ, Lee H, Hwang-Bo H, Ji SY, Kim MY, Hong SH, Jeong JW, Han MH, Choi SH, et al: Induction of G2/M cell cycle arrest and apoptosis by genistein in human bladder cancer T24 cells through Inhibition of the ROS-Dependent PI3k/Akt signal transduction pathway. Antioxidants (Basel). 8(327)2019.PubMed/NCBI View Article : Google Scholar

Wang Y, Wang H, Zhang W, Shao C, Xu P, Shi CH, Shi JG, Li YM, Fu Q, Xue W, et al: Genistein sensitizes bladder cancer cells to HCPT treatment in vitro and in vivo via ATM/NF-κB/IKK pathway-induced apoptosis. PLoS One. 8(e50175)2013.PubMed/NCBI View Article : Google Scholar

Köksal Karayildirim Ç, Nalbantsoy A and Karabay Yavaşoğlu NU: Prunetin inhibits nitric oxide activity and induces apoptosis in urinary bladder cancer cells via CASP3 and TNF-α genes. Mol Biol Rep. 48:7251–7259. 2021.PubMed/NCBI View Article : Google Scholar

Zhou YX, Zhang H and Peng C: Puerarin: A review of pharmacological effects. Phytother Res. 28:961–975. 2014.PubMed/NCBI View Article : Google Scholar

Jiang K, Chen H, Tang K, Guan W, Zhou H, Guo X, Chen Z, Ye Z and Xu H: Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway. Oncol Lett. 15:167–174. 2018.PubMed/NCBI View Article : Google Scholar

Ye G, Kan S, Chen J and Lu X: Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1/p53 pathway. Oncol Lett. 17:195–200. 2019.PubMed/NCBI View Article : Google Scholar

Jiang QQ, Liu B and Yuan T: MicroRNA-16 inhibits bladder cancer proliferation by targeting Cyclin D1. Asian Pac J Cancer Prev. 14:4127–4130. 2013.PubMed/NCBI View Article : Google Scholar

Liu X, Li S, Li Y, Cheng B, Tan B and Wang G: Puerarin inhibits proliferation and induces apoptosis by upregulation of miR-16 in bladder cancer cell line T24. Oncol Res. 26:1227–1234. 2018.PubMed/NCBI View Article : Google Scholar

Du L, Zhang L and Sun F: Puerarin inhibits the progression of bladder cancer by regulating circ_0020394/miR-328-3p/NRBP1 axis. Cancer Biother Radiopharm. 37:435–450. 2020.PubMed/NCBI View Article : Google Scholar

Wu Y, Zhang X, Li Z, Yan H, Qin J and Li T: Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of miR-21 and PTEN. Food Funct. 8:1061–1066. 2017.PubMed/NCBI View Article : Google Scholar

Ouyang Y, Li J, Chen X, Fu X, Sun S and Wu Q: Chalcone derivatives: Role in anticancer therapy. Biomolecules. 11(894)2021.PubMed/NCBI View Article : Google Scholar

Yuan X, Li D, Zhao H, Jiang J, Wang P, Ma X, Sun X and Zheng Q: Licochalcone A-induced human bladder cancer T24 cells apoptosis triggered by mitochondria dysfunction and endoplasmic reticulum stress. Biomed Res Int. 2013(474272)2013.PubMed/NCBI View Article : Google Scholar

Yang X, Jiang J, Yang X, Han J and Zheng Q: Licochalcone A induces T24 bladder cancer cell apoptosis by increasing intracellular calcium levels. Mol Med Rep. 14:911–919. 2016.PubMed/NCBI View Article : Google Scholar

Jiang J, Yuan X, Zhao H, Yan X, Sun X and Zheng Q: Licochalcone A inhibiting proliferation of bladder cancer T24 cells by inducing reactive oxygen species production. Biomed Mater Eng. 24:1019–1025. 2014.PubMed/NCBI View Article : Google Scholar

Hong SH, Cha HJ, Hwang-Bo H, Kim MY, Kim SY, Ji SY, Cheong J, Park C, Lee H, Kim GY, et al: Anti-proliferative and pro-apoptotic effects of licochalcone A through ROS-Mediated cell cycle arrest and apoptosis in human bladder cancer cells. Int J Mol Sci. 20(3820)2019.PubMed/NCBI View Article : Google Scholar

Zhao H, Yuan X, Jiang J, Wang P, Sun X, Wang D and Zheng Q: Antimetastatic effects of licochalcone B on human bladder carcinoma T24 by inhibition of matrix metalloproteinases-9 and NF-кB activity. Basic Clin Pharmacol Toxicol. 115:527–533. 2014.PubMed/NCBI View Article : Google Scholar

Yuan X, Li T, Xiao E, Zhao H, Li Y, Fu S, Gan L and Wang Z, Zheng Q and Wang Z: Licochalcone B inhibits growth of bladder cancer cells by arresting cell cycle progression and inducing apoptosis. Food Chem Toxicol. 65:242–251. 2014.PubMed/NCBI View Article : Google Scholar

Wang P, Yuan X, Wang Y, Zhao H, Sun X and Zheng Q: Licochalcone C induces apoptosis via B-cell lymphoma 2 family proteins in T24 cells. Mol Med Rep. 12:7623–7628. 2015.PubMed/NCBI View Article : Google Scholar

Wang KL, Yu TC and Hsia SM: Perspectives on the role of isoliquiritigenin in cancer. Cancers (Basel). 13(115)2021.PubMed/NCBI View Article : Google Scholar

Patricia Moreno-Londoño A, Bello-Alvarez C and Pedraza-Chaverri J: Isoliquiritigenin pretreatment attenuates cisplatin induced proximal tubular cells (LLC-PK1) death and enhances the toxicity induced by this drug in bladder cancer T24 cell line. Food Chem Toxicol. 109(Pt 1):143–154. 2017.PubMed/NCBI View Article : Google Scholar

Li X, Xu X, Ji T, Liu Z, Gu M, Hoang BH and Zi X: Dietary feeding of Flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice. Toxicol Rep. 1:2–11. 2014.PubMed/NCBI View Article : Google Scholar

Liu Z, Xu X, Li X, Liu S, Simoneau AR, He F, Wu XR and Zi X: Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model. Cancer Prev Res (Phila). 6:1365–1375. 2013.PubMed/NCBI View Article : Google Scholar

Liu Z, Song L, Xie J, Simoneau AR, Uchio E and Zi X: Chemoprevention of urothelial cell carcinoma tumorigenesis by dietary flavokawain A in UPII-Mutant Ha-ras transgenic mice. Pharmaceutics. 14(496)2022.PubMed/NCBI View Article : Google Scholar

Wu CM, Lin KW, Teng CH, Huang AM, Chen YC, Yen MH, Wu WB, Pu YS and Lin CN: Chalcone derivatives inhibit human platelet aggregation and inhibit growth in human bladder cancer cells. Biol Pharm Bull. 37:1191–1198. 2014.PubMed/NCBI View Article : Google Scholar

Martel-Frachet V, Keramidas M, Nurisso A, DeBonis S, Rome C, Coll JL, Boumendjel A, Skoufias DA and Ronot X: IPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma. Oncotarget. 6:14669–14686. 2015.PubMed/NCBI View Article : Google Scholar

Martel-Frachet V, Areguian J, Blanc M, Touquet B, Lamarca A, Ronot X and Boumendjel A: Investigation of a new 1,3-diarylpropenone as a potential antimitotic agent targeting bladder carcinoma. Anticancer Drugs. 20:469–476. 2009.PubMed/NCBI View Article : Google Scholar

Desilets A, Adam JP and Soulières D: Management of cisplatin-associated toxicities in bladder cancer patients. Curr Opin Support Palliat Care. 14:286–292. 2020.PubMed/NCBI View Article : Google Scholar

Cai Z, Zhang F, Chen W, Zhang J and Li H: MiRNAs: A promising target in the chemoresistance of bladder cancer. Onco Targets Ther. 12:11805–11816. 2019.PubMed/NCBI View Article : Google Scholar

Dobrzynska M, Napierala M and Florek E: Flavonoid nanoparticles: A promising approach for cancer therapy. Biomolecules. 10(1268)2020.PubMed/NCBI View Article : Google Scholar

Sun T, Zhang YS, Pang B, Hyun DC, Yang M and Xia Y: Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 53:12320–12364. 2014.PubMed/NCBI View Article : Google Scholar

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, et al: PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res. 49(D1):D1388–D1395. 2021.PubMed/NCBI View Article : Google Scholar

Patil M, Pabla N and Dong Z: Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci. 70:4009–4021. 2013.PubMed/NCBI View Article : Google Scholar

Schmitt E, Paquet C, Beauchemin M and Bertrand R: DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. J Zhejiang Univ Sci B. 8:377–397. 2007.PubMed/NCBI View Article : Google Scholar

Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F and Cui H: Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 5(8)2020.PubMed/NCBI View Article : Google Scholar